Anat Cell Biol.  2024 Mar;57(1):97-104. 10.5115/acb.23.158.

Ketone ester supplementation of Atkinstype diet prolongs survival in an orthotopic xenograft model of glioblastoma

• Azari H
• Poff A
• D’Agostino D
• Reynolds B

• KMID: 2554244
• DOI: http://doi.org/10.5115/acb.23.158

Abstract

Heavy reliance on glucose metabolism and a reduced capacity to use ketone bodies makes glioblastoma (GBM) a promising candidate for ketone-based therapies. Ketogenic diet (KD) is well-known for its promising effects in controlling tumor growth in GBM. Moreover, synthetic ketone ester (KE) has demonstrated to increase blood ketone levels and enhance animal survival in a metastatic VM-M3 murine tumor model. Here, we compared the efficacy of a KE-supplemented Atkins-type diet (ATD-KE) to a classic KD in controlling tumor progression and enhancing survival in a clinically relevant orthotopic patient-derived xenograft GBM model. Our findings demonstrate that ATD-KE preserves body weight (percent change from the baseline; 112±2.99 vs. 116.9±2.52 and 104.8±3.67), decreases blood glucose (80.55±0.86 vs. 118.6±9.51 and 52.35±3.89 mg/dl), and increases ketone bodies in blood (1.15±0.03 mM vs. 0.55±0.04 and 2.66±0.21 mM) and brain tumor tissue (3.35±0.30 mM vs. 2.04±0.3 and 4.25±0.25 mM) comparable to the KD (results presented for ATD-KE vs. standard diet [STD] and KD, respectively). Importantly, the ATD-KE treatment significantly enhanced survival compared to the STD and was indistinguishable from the KD (47 days in STD vs. 56 days in KD and ATD-KE), suggesting that a nutritionally balanced low carbohydrate ATD combined with KE may be as effective as the KD alone in reducing brain tumor progression. Overall, these data support the rationale for clinical testing of KE-supplemented low-carb diet as an adjunct treatment for brain tumor patients.

Keyword

Glioblastoma; Ketone ester; Ketone bodies; Tumor progression; Survival

Figure

• 

  Fig. 1 Weight change, blood glucose, and ketone levels in NOD/SCID mice treated with different dietary interventions. (A) Body weight was presented as a percent of weight at the start of dietary intervention. Animals in KD and KE supplemented diet groups lost weight in the first week. KD remained unchanged over the rest of the study period but STD+KE and ATD+KE animals reached a plateau after decreasing KE from 20% to 10% in their food. (B, C) Three weeks after putting animals on the diets, the average blood glucose and β-hydroxybutyrate (β-HB) levels were measured over a course of 12 hours. (D) Blood acetoacetate (AcAc) was also measured only at the 12-hour time-point. Animals on the KD and ATD+KE had significantly lower glucose levels compared to the STD (control diet). Although the highest levels of β-HB were observed in the KD treated animals, the β-HB levels in the ATD+KE and STD+KE animals were significantly higher than the STD alone group. Additionally, AcAc in KD and ATD+KE and STD+KE were significantly higher than the STD alone group (*P<0.05, **P<0.0021, ***P<0.0002, ****P<0.0001; one-way ANOVA). KD, ketogenic diet; STD, standard diet; ATD, Atkins-type diet; KE, ketone ester.

• 

  Fig. 2 Weight change, blood glucose, and ketone levels in brain tumor bearing NOD/SCID mice under STD, ATD+KE, and KD dietary interventions. (A) Body weight was presented as a percent of weight at the start of dietary intervention. Compared to STD, no statistically significant changes occurred in animals’ body weight. (B) Both the KD and ATD+KE had significantly lower glucose compared to the STD group, and also glucose level in the KD group was significantly lower than the ATD+KE. (C) β-hydroxybutyrate (β-HB) was significantly higher in the KD as compared to the STD and ATD+KE groups. Moreover, β-HB level in ATD+KE was also significantly elevated relative to the STD alone group (**P<0.0021, ****P<0.0001; one-way ANOVA). KD, ketogenic diet; STD, standard diet; ATD, Atkins-type diet; KE, ketone ester.

• 

  Fig. 3 (A) Kaplan–Meier survival curve with stratified Max-Combo test demonstrated a significant survival benefit of both KD (***P=0.0003) and ATD+KE (**P=0.002) dietary interventions compared to STD in L0 tumor bearing NOD/SCID mice. (B) Measurements of β-hydroxybutyrate (β-HB) from tumor tissue demonstrated a significant increase of intra-tumoral β-HB under both dietary interventions. (C) Intra-tumoral AcAc levels were elevated but were not significantly different when compared to controls (*P<0.05, **P<0.0021; one-way ANOVA). KD, ketogenic diet; STD, standard diet; ATD, Atkins-type diet; KE, ketone ester; AcAc, acetoacetate.

Reference

References

1. Gallia GL, Brem S, Brem H. 2005; Local treatment of malignant brain tumors using implantable chemotherapeutic polymers. J Natl Compr Canc Netw. 3:721–8. DOI: 10.6004/jnccn.2005.0042. PMID: 16194460.

2. Hau P, Baumgart U, Pfeifer K, Bock A, Jauch T, Dietrich J, Fabel K, Grauer O, Wismeth C, Klinkhammer-Schalke M, Allgäuer M, Schuierer G, Koch H, Schlaier J, Ulrich W, Brawanski A, Bogdahn U, Steinbrecher A. 2003; Salvage therapy in patients with glioblastoma: is there any benefit? Cancer. 98:2678–86. DOI: 10.1002/cncr.11845. PMID: 14669289.

3. Arismendi-Morillo GJ, Castellano-Ramirez AV. 2008; Ultrastructural mitochondrial pathology in human astrocytic tumors: potentials implications pro-therapeutics strategies. J Electron Microsc (Tokyo). 57:33–9. DOI: 10.1093/jmicro/dfm038. PMID: 18230641.

4. Chinopoulos C, Seyfried TN. 2018; Mitochondrial substrate-level phosphorylation as energy source for glioblastoma: review and hypothesis. ASN Neuro. 10:1759091418818261. DOI: 10.1177/1759091418818261. PMID: 30909720. PMCID: PMC6311572.

5. Hoang-Minh LB, Siebzehnrubl FA, Yang C, Suzuki-Hatano S, Dajac K, Loche T, Andrews N, Schmoll Massari M, Patel J, Amin K, Vuong A, Jimenez-Pascual A, Kubilis P, Garrett TJ, Moneypenny C, Pacak CA, Huang J, Sayour EJ, Mitchell DA, Sarkisian MR, Reynolds BA, Deleyrolle LP. 2018; Infiltrative and drug-resistant slow-cycling cells support metabolic heterogeneity in glioblastoma. EMBO J. 37:e98772. DOI: 10.15252/embj.201798772. PMID: 30322894. PMCID: PMC6276884.

6. Mukherjee P, Augur ZM, Li M, Hill C, Greenwood B, Domin MA, Kondakci G, Narain NR, Kiebish MA, Bronson RT, Arismendi-Morillo G, Chinopoulos C, Seyfried TN. 2019; Therapeutic benefit of combining calorie-restricted ketogenic diet and glutamine targeting in late-stage experimental glioblastoma. Commun Biol. 2:200. DOI: 10.1038/s42003-019-0455-x. PMID: 31149644. PMCID: PMC6541653.

7. Vallejo FA, Shah SS, de Cordoba N, Walters WM, Prince J, Khatib Z, Komotar RJ, Vanni S, Graham RM. 2020; The contribution of ketone bodies to glycolytic inhibition for the treatment of adult and pediatric glioblastoma. J Neurooncol. 147:317–26. DOI: 10.1007/s11060-020-03431-w. PMID: 32096068.

8. Badr CE, Silver DJ, Siebzehnrubl FA, Deleyrolle LP. 2020; Metabolic heterogeneity and adaptability in brain tumors. Cell Mol Life Sci. 77:5101–19. DOI: 10.1007/s00018-020-03569-w. PMID: 32506168. PMCID: PMC8272080.

9. Deleyrolle LP, Harding A, Cato K, Siebzehnrubl FA, Rahman M, Azari H, Olson S, Gabrielli B, Osborne G, Vescovi A, Reynolds BA. 2011; Evidence for label-retaining tumour-initiating cells in human glioblastoma. Brain. 134(Pt 5):1331–43. DOI: 10.1093/brain/awr081. PMID: 21515906. PMCID: PMC3097894.

10. Ramirez YP, Weatherbee JL, Wheelhouse RT, Ross AH. 2013; Glioblastoma multiforme therapy and mechanisms of resistance. Pharmaceuticals (Basel). 6:1475–506. DOI: 10.3390/ph6121475. PMID: 24287492. PMCID: PMC3873674.

11. Lussier DM, Woolf EC, Johnson JL, Brooks KS, Blattman JN, Scheck AC. 2016; Enhanced immunity in a mouse model of malignant glioma is mediated by a therapeutic ketogenic diet. BMC Cancer. 16:310. DOI: 10.1186/s12885-016-2337-7. PMID: 27178315. PMCID: PMC4866042.

12. Martuscello RT, Vedam-Mai V, McCarthy DJ, Schmoll ME, Jundi MA, Louviere CD, Griffith BG, Skinner CL, Suslov O, Deleyrolle LP, Reynolds BA. 2016; A supplemented high-fat low-carbohydrate diet for the treatment of glioblastoma. Clin Cancer Res. 22:2482–95. DOI: 10.1158/1078-0432.CCR-15-0916. PMID: 26631612.

13. Poff AM, Ari C, Arnold P, Seyfried TN, D'Agostino DP. 2014; Ketone supplementation decreases tumor cell viability and prolongs survival of mice with metastatic cancer. Int J Cancer. 135:1711–20. DOI: 10.1002/ijc.28809. PMID: 24615175. PMCID: PMC4235292.

14. Stafford P, Abdelwahab MG, Kim DY, Preul MC, Rho JM, Scheck AC. 2010; The ketogenic diet reverses gene expression patterns and reduces reactive oxygen species levels when used as an adjuvant therapy for glioma. Nutr Metab (Lond). 7:74. DOI: 10.1186/1743-7075-7-74. PMID: 20831808. PMCID: PMC2949862.

15. Rieger J, Bähr O, Maurer GD, Hattingen E, Franz K, Brucker D, Walenta S, Kämmerer U, Coy JF, Weller M, Steinbach JP. 2014; ERGO: a pilot study of ketogenic diet in recurrent glioblastoma. Int J Oncol. 44:1843–52. Erratum in: Int J Oncol 2014;45: 2605. DOI: 10.3892/ijo.2014.2382. PMID: 24728273. PMCID: PMC4063533.

16. Rahman M, Azari H, Deleyrolle L, Millette S, Zeng H, Reynolds BA. 2013; Controlling tumor invasion: bevacizumab and BMP4 for glioblastoma. Future Oncol. 9:1389–96. DOI: 10.2217/fon.13.96. PMID: 23980685.

17. D'Agostino DP, Pilla R, Held HE, Landon CS, Puchowicz M, Brunengraber H, Ari C, Arnold P, Dean JB. 2013; Therapeutic ketosis with ketone ester delays central nervous system oxygen toxicity seizures in rats. Am J Physiol Regul Integr Comp Physiol. 304:R829–36. DOI: 10.1152/ajpregu.00506.2012. PMID: 23552496.

18. Akazawa K, Nakamura T, Palesch Y. 1997; Power of logrank test and Cox regression model in clinical trials with heterogeneous samples. Stat Med. 16:583–97. DOI: 10.1002/(SICI)1097-0258(19970315)16:5<583::AID-SIM433>3.0.CO;2-Z.

19. Ye F, Li XJ, Jiang WL, Sun HB, Liu J. 2015; Efficacy of and patient compliance with a ketogenic diet in adults with intractable epilepsy: a meta-analysis. J Clin Neurol. 11:26–31. DOI: 10.3988/jcn.2015.11.1.26. PMID: 25628734. PMCID: PMC4302176.

20. Nakamura K, Tonouchi H, Sasayama A, Ashida K. 2018; A ketogenic formula prevents tumor progression and cancer cachexia by attenuating systemic inflammation in colon 26 tumor-bearing mice. Nutrients. 10:206. DOI: 10.3390/nu10020206. PMID: 29443873. PMCID: PMC5852782.

21. Kashiwaya Y, Pawlosky R, Markis W, King MT, Bergman C, Srivastava S, Murray A, Clarke K, Veech RL. 2010; A ketone ester diet increases brain malonyl-CoA and Uncoupling proteins 4 and 5 while decreasing food intake in the normal Wistar Rat. J Biol Chem. 285:25950–6. DOI: 10.1074/jbc.M110.138198. PMID: 20529850. PMCID: PMC2923987.

22. Karrison TG. 2016; Versatile tests for comparing survival curves based on weighted log-rank statistics. Stata J. 16:678–90. DOI: 10.1177/1536867X1601600308.

23. Knezevic A, Patil S. Combination weighted log-rank tests for survival analysis with non-proportional hazards. In : SAS Global Forum; 2020.

24. Lin RS, Lin J, Roychoudhury S, Anderson KM, Hu T, Huang B, Leon LF, Liao JJZ, Liu R, Luo X, Mukhopadhyay P, Qin R, Tatsuoka K, Wang X, Wang Y, Zhu J, Chen TT, Iacona R. 2020; Alternative analysis methods for time to event endpoints under nonproportional hazards: a comparative analysis. Stat Biopharm Res. 12:187–98. DOI: 10.1080/19466315.2019.1697738.

25. Seyfried TN, Arismendi-Morillo G, Mukherjee P, Chinopoulos C. 2020; On the origin of ATP synthesis in cancer. iScience. 23:101761. DOI: 10.1016/j.isci.2020.101761. PMID: 33251492. PMCID: PMC7677709.

26. Chang HT, Olson LK, Schwartz KA. 2013; Ketolytic and glycolytic enzymatic expression profiles in malignant gliomas: implication for ketogenic diet therapy. Nutr Metab (Lond). 10:47. DOI: 10.1186/1743-7075-10-47. PMID: 23829383. PMCID: PMC3707813.

27. Park SJ, Smith CP, Wilbur RR, Cain CP, Kallu SR, Valasapalli S, Sahoo A, Guda MR, Tsung AJ, Velpula KK. 2018; An overview of MCT1 and MCT4 in GBM: small molecule transporters with large implications. Am J Cancer Res. 8:1967–76.